Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2019
Electrical impedance myography as a biomarker of inclusion body myositis: A cross-sectional study.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roy Bhaskar, Rutkove Seward B, Nowak Richard J
Аннотация
OBJECTIVE: To assess the value of electrical impedance myography (EIM) in inclusion body myositis (IBM).
METHODS: Patients with clinically defined IBM and healthy controls (HC) of similar age group were recruited. Each participant underwent manual muscle testing (MMT), 6-min walk test (6MWT), handgrip dynamometry, and IBM-functional rating scale assessment (IBM-FRS). EIM measurements were obtained from bilateral deltoid, biceps, forearm-flexors, quadriceps, tibialis anterior, and medial gastrocnemius.
RESULTS: Fourteen IBM patients and 12 HCs with mean age 68.6 ± 6 and 67.4 ± 5.4 years were included in the final analysis. Averaged phase value at 50 kHz (EIM50) and ratio of phase value at 50 kHz/200 kHz (EIMPR) from six-muscles were significantly lower in IBM patients when compared to HC (5.23 ± 1.34 vs 7.88 ± 1.9, p-value 0.002, and 0.55 ± 0.09 vs. 0.68 ± 0.09, p-value 0.004, respectively). A strong correlation was noted between IBM-FRS, 6MWT, disease-duration and the averaged value of EIM50 and EIMPR in the IBM patients (Spearman |rho|>0.7, p-values < 0.01).
CONCLUSIONS: EIM can differentiate between IBM patients and HCs and EIM parameters correlate with clinical outcome measures.
SIGNIFICANCE: EIM may be a potential objective biomarker for IBM. A longitudinal validation study is warranted.
METHODS: Patients with clinically defined IBM and healthy controls (HC) of similar age group were recruited. Each participant underwent manual muscle testing (MMT), 6-min walk test (6MWT), handgrip dynamometry, and IBM-functional rating scale assessment (IBM-FRS). EIM measurements were obtained from bilateral deltoid, biceps, forearm-flexors, quadriceps, tibialis anterior, and medial gastrocnemius.
RESULTS: Fourteen IBM patients and 12 HCs with mean age 68.6 ± 6 and 67.4 ± 5.4 years were included in the final analysis. Averaged phase value at 50 kHz (EIM50) and ratio of phase value at 50 kHz/200 kHz (EIMPR) from six-muscles were significantly lower in IBM patients when compared to HC (5.23 ± 1.34 vs 7.88 ± 1.9, p-value 0.002, and 0.55 ± 0.09 vs. 0.68 ± 0.09, p-value 0.004, respectively). A strong correlation was noted between IBM-FRS, 6MWT, disease-duration and the averaged value of EIM50 and EIMPR in the IBM patients (Spearman |rho|>0.7, p-values < 0.01).
CONCLUSIONS: EIM can differentiate between IBM patients and HCs and EIM parameters correlate with clinical outcome measures.
SIGNIFICANCE: EIM may be a potential objective biomarker for IBM. A longitudinal validation study is warranted.